MCT
Evidence Fact Sheet
Medium-Chain Triglycerides
Medium-chain triglycerides (MCT, mainly C8/C10) are rapidly oxidized fats transported via the portal vein to the liver, generating ketones. Research finds modest weight reduction and lower energy intake vs long-chain fat, higher diet-induced thermogenesis, mild ketosis with possible cognition effects, but a neutral-to-slightly-adverse blood-lipid profile. US GRAS; no authorized EU health claim.
Also known as: Medium-chain triglycerides · MCT oil · C8 caprylic acid · C10 capric acid · Fractionated coconut oil
Overview
MCT (medium-chain triglycerides) are dietary fats of 6-12 carbon chain length, predominantly caprylic (C8) and capric (C10) acids derived from coconut/palm-kernel fractionation. Unlike long-chain triglycerides, they are absorbed directly into the portal vein and undergo carnitine-shuttle-independent rapid hepatic beta-oxidation, driving ketogenesis (beta-hydroxybutyrate / acetoacetate) and a higher rate of diet-induced thermogenesis. Research and practice doses are typically MCT oil 15-30 g/day substituted for an equal amount of dietary fat (started low to limit GI upset), with C8-rich preparations favored for ketone production. In the US, MCT is GRAS (GRN 1049, 2022) and used as a dietary-supplement/functional-food ingredient; the EU has authorized no MCT health claims (EFSA rejected weight-management, energy-expenditure and body-fat claims in 2011), and it is a permitted food ingredient in China, Brazil and other markets.
Mechanism of Action
Portal-vein direct transport to liver (carnitine-shuttle-independent rapid β-oxidation) · Hepatic ketogenesis (BHB / acetoacetate generation) · Increased diet-induced thermogenesis (faster oxidation than LCT) · AMPK activation via energy-metabolism flux · Decanoic acid (C10) direct AMPA-receptor modulation (mechanistic / preclinical context)
Body systems: Mitochondrial & Cellular Energy · METABOLISM · Body Composition · Digestive & Gut · CNS
Evidence-Based Benefits
Each benefit below is anchored to a specific PubMed-indexed study. Effect sizes, sample sizes, and p-values are reported as published; no values are inferred. Honest negatives and null results are kept alongside the positive findings, and disease-research populations are described as such — MCT is not characterized as a treatment for any disease.
Body-Weight Management (vs Long-Chain Fat Substitution)
Meta-analysis supported- WMD −1.53%weight vs LCT · p<0.01
- −2.44, −0.6395% CI
- WMD −1.62%pure MCT subgroup
In a systematic review and meta-analysis of adults with overweight or obesity, substituting MCT for long-chain fat produced a modest but statistically significant reduction in body weight versus long-chain-fatty-acid diets. The effect was somewhat larger for pure MCTs, while medium-long-chain triglyceride (MLCT) blends did not significantly reduce weight — so the benefit is real but small and depends on composition.
Reported effect: MCT-enriched diets reduced weight WMD: −1.53%; 95% CI: −2.44, −0.63; p < 0.01 vs LCT; pure MCTs WMD: −1.62%; 95% CI: −2.78, −0.46; p < 0.01
“MCT-enriched diets produced weight reduction with WMD: -1.53%; 95% CI: -2.44, -0.63; p < 0.01 compared to long-chain fatty acid diets. Pure MCTs showed greater effectiveness: WMD: -1.62%; 95% CI: -2.78, -0.46; p < 0.01. An MLCTs-enriched diet did not significantly reduce weight loss.”
Source: PMID 38936302 · He 2024 · Clin Nutr
Acute Satiety & Energy Intake
Meta-analysis supported- ES −0.444ad libitum energy intake · p<0.017
- −0.808, −0.08095% CI
- 11 studies · 291trials · participants
A systematic review and meta-analysis found that MCT ingestion produced a statistically significant moderate decrease in subsequent ad libitum energy intake compared with long-chain triglycerides under laboratory conditions. Notably, this occurred despite little evidence of any effect on subjective appetite ratings or circulating appetite hormones — suggesting a mechanism distinct from felt hunger suppression.
Reported effect: ad libitum energy intake mean effect size −0.444 (95% CI −0.808, −0.080, p < 0.017); 11 studies, 291 participants; no significant effect on subjective appetite or hormones
“Synthesis of combined data showed evidence of a statistically significant moderate decrease in ad libitum energy intake after both acute and chronic ingestion of MCT compared to LCT when assessed under laboratory conditions (mean effect size: -0.444, 95% CI -0.808, -0.080, p < 0.017), despite little evidence of any effect of MCT on subjective appetite ratings or circulating hormones.”
Source: PMID 32212947 · Maher 2021 · Crit Rev Food Sci Nutr
Diet-Induced Thermogenesis (vs Long-Chain Fat)
Meta-analysis supportedIn a systematic review with meta-analyses of diet-induced thermogenesis (DIT), meals containing medium-chain triglycerides produced a significantly higher thermogenic response than meals with long-chain triglycerides. The comparison reached statistical significance, though the abstract reports the result as a p-value rather than a thermogenic magnitude.
Effect size: not quantified on this page — see the linked study below for the reported figures.
Source: PMID 27792142 · Quatela 2016 · Nutrients
Ketosis & Cognition (Mild Cognitive Impairment / Alzheimer's)
Meta-analysis supportedA systematic review and meta-analysis of human studies in mild cognitive impairment and Alzheimer's disease found MCT reliably induced mild ketosis (raised beta-hydroxybutyrate) and a small significant improvement on a combined cognition measure. Honest nuance: ADAS-Cog alone showed only a non-significant trend, and the authors caution that risk of bias necessitates future trials — so the cognitive signal is preliminary, not established.
Effect size: not quantified on this page — see the linked study below for the reported figures.
Source: PMID 31870908 · Avgerinos 2020 · Ageing Res Rev
Blood Lipids (LDL-C / HDL-C / Triglycerides)
Null / no benefit Meta-analysis supported- LDL +0.02 mmol/Lnull · CI −0.13, 0.17
- HDL −0.01 mmol/Lnull · CI −0.10, 0.09
- TG +0.14 mmol/Lincrease · CI 0.01, 0.27
Honest negative: a systematic review and meta-analysis of randomized trials found MCT oil does not significantly change total, LDL or HDL cholesterol, but does cause a small statistically significant increase in triglycerides. This tempers the metabolic-benefit narrative and is why lipid effects should be disclosed honestly rather than framed as cardioprotective.
Reported effect: Total cholesterol 0.04 mmol/L (95% CI −0.11, 0.20); LDL 0.02 mmol/L (95% CI −0.13, 0.17); HDL −0.01 mmol/L (95% CI −0.10, 0.09); triglycerides 0.14 mmol/L (95% CI 0.01, 0.27); 7 articles
“Total Cholesterol: 0.04 mmol/L (95% CI, -0.11 to 0.20) — null; LDL Cholesterol: 0.02 mmol/L (95% CI, -0.13 to 0.17) — null; HDL Cholesterol: -0.01 mmol/L (95% CI, -0.10 to 0.09) — null; Triglycerides: 0.14 mmol/L (95% CI, 0.01-0.27) — statistically significant increase. MCT oil does not affect total cholesterol, LDL cholesterol, or HDL cholesterol levels, but does cause a small increase in triglycerides.”
Source: PMID 34255085 · McKenzie 2021 · J Nutr
Dosage (research context · not a recommendation)
Research/practice range: MCT oil 15-30 g/day (1-2 tbsp), substituting an equal amount of dietary fat (not added on top); C8-rich for ketogenesis split across meals. "Start low, go slow" (begin ~5 g/day, increase ~5 g every 3-5 days) to limit GI upset; single doses >30 g frequently cause GI distress. MCT oil ~8.3 kcal/g.
Regulatory Status · 4 Markets
- US · FDA
- GRAS (GRN 1049 · Medium-chain triacylglycerols · 2022 · no questions); DSHEA dietary supplement / functional food; structure-function claims used in US market; ~305 DSLD products (median 3000 mg softgel · 15 mL liquid serving). No FDA authorized/qualified health claim for MCT.
- EU · EFSA
- 0 authorized health claims — EFSA rejected 3 Art.13(1) claims (weight management / energy expenditure / body-fat reduction) in 2011 (EFSA Journal 2011;9(6):2240). Legal food ingredient (no Novel Food barrier) but no permitted health claim.
- CN · China
- Permitted as conventional food ingredient in China (listed in GB 2760 food-additive standard; coconut-oil fractionation product used as common food raw material; allowed in FSMP and infant formula).
- BR · ANVISA
- Permitted as a fat source in foods and dietary supplements (RDC 243/2018 framework); long history in enteral/medical nutrition (FSMP). Functional claims assessed case-by-case; no standing MCT-specific authorized functional claim.
Safety
Generally well tolerated (FDA GRAS GRN 1049, 2022). Dose-limiting GI effects (nausea, cramping, diarrhea) — single doses >30 g poorly tolerated. Caution in severe hepatic insufficiency (MCT is metabolized directly in the liver via portal vein). Type 1 diabetes: ketogenic effect may raise diabetic-ketoacidosis (DKA) risk — monitor. Carbon-chain composition matters: C12 (lauric) behaves more like LCT with far lower ketogenic efficiency than C8, so "MCT/ketogenic" framing requires C8/C10 disclosure. Lipid note: meta-analysis (McKenzie 2021) found no significant LDL-C/HDL-C change but a triglyceride increase — present honestly.
Related
Goals: weight-management
Lifestyles: keto
References
PubMed-indexed citations anchoring the benefit findings above. Effect sizes are reported as published.
- PMID 38936302 · He 2024 · Clin Nutr — Body-Weight Management (vs Long-Chain Fat Substitution)
- PMID 32212947 · Maher 2021 · Crit Rev Food Sci Nutr — Acute Satiety & Energy Intake
- PMID 27792142 · Quatela 2016 · Nutrients — Diet-Induced Thermogenesis (vs Long-Chain Fat)
- PMID 31870908 · Avgerinos 2020 · Ageing Res Rev — Ketosis & Cognition (Mild Cognitive Impairment / Alzheimer's)
- PMID 34255085 · McKenzie 2021 · J Nutr — Blood Lipids (LDL-C / HDL-C / Triglycerides)
Frequently Asked Questions
1. Does MCT actually help with weight loss?
The evidence points to a modest effect, not a dramatic one. A 2024 meta-analysis (He, Clin Nutr) found that substituting MCT for long-chain fat reduced body weight by about WMD −1.53% versus long-chain-fatty-acid diets, with a slightly larger effect for pure MCTs. The key is substitution — replacing other dietary fat with MCT, not adding it on top of an existing diet. Effects are small and composition-dependent, so MCT is best understood as a marginal metabolic lever rather than a primary weight-loss tool.
2. Why might MCT reduce how much I eat if it doesn't make me feel full?
That distinction is one of the more interesting findings. The 2021 satiety meta-analysis (Maher, Crit Rev Food Sci Nutr) found MCT produced a moderate decrease in ad libitum energy intake (effect size −0.444) under laboratory conditions, yet showed little effect on subjective appetite ratings or circulating appetite hormones. In other words, people ate somewhat less without necessarily reporting feeling fuller — a physiological signal that appears distinct from conscious hunger suppression.
3. What's the honest downside on blood lipids?
MCT is not lipid-neutral in a fully favorable way. The randomized-trial meta-analysis (McKenzie 2021, J Nutr) found no significant change in total, LDL or HDL cholesterol, but a small statistically significant increase in triglycerides (+0.14 mmol/L). This is why responsible reporting discloses the triglyceride signal rather than framing MCT as cardioprotective.
4. How is MCT regulated?
In the US, MCT is GRAS (FDA GRN 1049, 2022, no questions) and used as a dietary-supplement and functional-food ingredient under DSHEA structure-function framing, with no FDA authorized or qualified health claim. The EU has authorized zero MCT health claims — EFSA rejected weight-management, energy-expenditure and body-fat-reduction claims in 2011 — though it remains a legal food ingredient. It is also a permitted food ingredient in China and Brazil.
Last evidence review: 2026-06-13